Fate Therapeutics, Inc. vs UnitedHealth Group Incorporated — Stock Comparison
Q·Score Breakdown
5.4
Bearish
Overall
6.3
Neutral
Quality
Health
Growth
Valuation
Sentiment
FATE
Clean balance sheet with low leverage (0.4× debt-to-equity).
⚠ low return on equity (-52%).
UNH
82% of 28 covering analysts have a positive rating.
⚠ limited growth momentum.
Analyst Consensus
HOLD
Target $5.19 (+239.1%)
8 analysts
BUY
Target $387.27 (+5.0%)
26 analysts
Fundamentals
FATE
UNH
—
Trailing P/E
27.9×
-1.5×
Forward P/E
17.8×
0.0%
Profit Margin
2.7%
0.0%
Gross Margin
18.8%
-51.8%
ROE
12.2%
-26.4%
Revenue Growth
2.0%
—
Earnings Growth
0.7%
2.24
Beta
0.41
—
Price / Book
—
$178M
Market Cap
$334.9B
$1 – $2
52-Week Range
$235 – $410
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →